Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Morphologically confirmed acute myeloid leukemia of 1 of the following subtypes:
• •Acute myeloblastic leukemia (M0, M1, M2)
• •Acute myelomonocytic leukemia (M4)
• •Acute monocytic leukemia (M5)
• •Acute erythroleukemia (M6)
• •Acute megakaryocytic leukemia (M7)
• •Must have 1 of the following karyotypic abnormalities at the time of diagnosis:
• •Complex cytogenetic abnormalities (≥ 3 cytogenetic clones)
• •Abnormalities of chromosome 5 \[-5 or del(5q)\]
• •Abnormalities of the long (q) arm of chromosome 3, 9, 11, 20, or 21
• •Abnormalities of the short (p) arm of chromosome 17, monosomy 7, t(9;22), or t(6;9) (8)
• •In morphologic first complete remission\*, as evidenced by all of the following for ≥ 4 weeks before study entry:
• •Absolute neutrophil count \> 1,000/mm\^3
• •Platelet count \> 100,000/mm\^3
• •Leukemic blasts not present in the peripheral blood
• •Cellularity of bone marrow biopsy \> 20% with maturation of all cell lines
• •Less than 5% blasts by bone marrow biopsy
• •No extramedullary leukemia, such as CNS or soft tissue involvement NOTE: \*Reduced hemoglobin concentration or hematocrit has no bearing on remission status
• •Haploidentical (3/6 or 4/6 antigen matched \[A, B, and DR\]) family donor available
• •PATIENT CHARACTERISTICS:
• •Age
• •18 to 59
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •See Disease Characteristics
• •Hepatic
• •Bilirubin ≤ 2.0 mg/dL
• •AST \< 2 times upper limit of normal
• •Renal
• •Creatinine ≤ 1.5 mg/dL
• •Cardiovascular
• •Ejection fraction \> 40% by MUGA or echocardiogram
• •None of the following within the past 3 months:
• •Myocardial infarction
• •Significant congestive heart failure
• •Significant cardiac arrhythmia
• •Pulmonary
• •FEV\_1 and DLCO \> 50% of predicted
• •Immunologic
• •HIV negative
• •No active or unresolved infection
• •No evidence of invasive fungal infection (e.g., positive blood or deep tissue cultures or stains)
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No organ damage
• •No other medical problem that would preclude study participation
• •No other currently active tumor that would likely interfere with study treatment or that would likely compromise the patient's morbidity or mortality
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No concurrent routine use of filgrastim (G-CSF) or sargramostim (GM-CSF) to accelerate hematopoietic recovery post-transplantation
• •Chemotherapy
• •More than 4 weeks since prior chemotherapy
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •More than 4 weeks since prior radiotherapy
• •Surgery
• •Not specified